

CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

Date: **15-05-2025**

To,
Department of Corporate Service,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

SCRIP CODE: **519242**

Subject: - Outcome of the meeting of the Board of Directors of Sarda Proteins Limited (“the Company”) in accordance with Regulation 29 and 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (“Listing Regulation”)

Dear Sir / Madam,

With reference to the captioned subject and in terms of the provisions of Regulation 29 and 30 of Listing Regulations, we wish to inform your good office that the Board of Directors of the Company, at their meeting held today i.e., Thursday 15th May, 2025, have, inter alia, transacted and approved the following businesses:

1. Approved the Audited Financial Results of the Company for the quarter and Financial Year ended as on 31st March, 2025.
2. The Board of Director has appointed Krina Gokulkumar Shah, Practicing Company Secretary as Secretarial Auditor for the financial year 2025-26.

The details as required under SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09th September, 2015 are provided in “Annexure-I”

The meeting started at 04:30 PM and concluded at 05:20 PM.

Kindly take aforesaid mentioned documents on your records.

Thanking you,

Yours faithfully,

For, Sarda Proteins Limited

Khilan H. Savaliya

Director

DIN: 08790209

“ANNEXURE-I”

Disclosure of events and information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

S.N.	Particulars	Details
1.	Reason for change viz appointment, resignation, removal, death or otherwise	Appointment: to comply with the provisions of the Section 204 of the Companies Act, 2013 and Regulation 24A of the Listing Regulations.
2.	Date and Term of Appointment	Date: 15 th May, 2025 Krina Gokulkumar Shah, Practicing Company Secretary (Membership No. A66521, COP No. 27764) as a Secretarial Auditor for the financial year 2025-26
3.	Brief Profile (in case of appointment)	
	Name of Auditor	Krina Gokulkumar Shah, Practicing Company Secretary (Membership No. A66521, COP No. 27764) Peer Review Certificate No. 6518/2025
	Office Address	D-403, ICB City, Vandematram Road, Gota, Ahmedabad, Gujarat-382481, India
	Email Id	krinashah9160@gmail.com
	About Auditor	Having approximately 8 years of working experience in Legal, Finance, Accounts and Taxation. Have worked with different corporates including listed entities during this time span. Have been designated as Chief Financial Officer while working with organizations and having experience of leading Team and Managerial requirements. Having vast experience in Company Incorporation (including Wholly Owned Subsidiaries, ROC Compliances, Drafting of Agreements (Commercial and others) / letters / replies, Handling litigations, Departmental appearances. Have handled listed entities NSE / BSE and SEBI compliances.
	Disclosure of relationships between directors (in case of Appointment of a Director)	Not Applicable

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)

Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)

Contact No.: +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com



S K AGARWAL & ASSOCIATES

Chartered Accountants

111, 1st Floor, Ganpati Mall, Samtal Road, Bhiwadi-301019 (Raj.)

Mob : 9828115580 | Email : cabhiwadi@gmail.com

INDEPENDENT AUDITOR'S REPORT

Independent Auditor's Report on the Quarterly and Year to Date Standalone Audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
The Board of Directors of
SARDA PROTEINS LTD
B-536-537, Matsya Industrial Area,
Alwar, Rajasthan- 301030

Report on the Audit of the Financial Results

Opinion

We have audited the accompanying statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2025 ("Statement") of Sarda Proteins Ltd ("the Company"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement;

- a. Is presented in accordance with the requirements of the Listing Regulations in this regard; and
- b. Gives a true and fair view in conformity with the applicable Indian Accounting Standards (IAS) as prescribed under section 133 of the Companies Act 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India, of the net profit and total comprehensive income and other financial information of the company for the quarter and year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results



under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion on the Financial Results.

Management's Responsibilities for the Financial Results

This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related Statement. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the applicable Accounting Standards prescribed under section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulations 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement, that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are also responsible for assessing the Company's ability to continue as going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Financial Reporting process of the Company.

Auditor's Responsibilities for the audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.



We also:

- (a) Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omission, misrepresentations, or the override of internal control.
- (b) Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion through a separate report on the complete set off financial statements on whether the company has adequate internal financial controls system with reference to financial statements in place and the operating effectiveness of such controls.
- (c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- (d) Conclude on the appropriateness of Board of Directors'/ management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- (e) Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the statement represent the underlying transactions and events in a manner that achieves fair presentation.
- (f) Obtain sufficient appropriate audit evidence regarding the Annual Financial Results of the company to express an opinion on the Annual Financial Results.

Materiality is the magnitude of misstatements in the statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Others Matters

The statement includes Financial Results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, as required under the Listing Regulations.

Our opinion on the statement is not modified in respect of the above matter.

For S K Agarwal & Associates
Chartered Accountants
FRN: 014841C



CA Sushil Kumar Agarwal
Partner
M. No.: 403073
UDIN : 25403073BMJOFF5582
Place : Rajkot
Date : 15.05.2025



SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
 EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com
 CIN: L15142RJ1991PLC006353

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH 2025

Rs.in Lakhs

S. No.	Particulars	Quarter Ended on			Year Ended on	
		31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024
		Audited	Un-Audited	Audited	Audited	Audited
I	Revenue from Operations	-	-	6.01	2,419.10	129.58
II	Other Income	-	0.06	4.10	0.06	16.53
III	Total Income (I+II)	-	2,405.16	10.11	2,419.17	146.11
IV	Expenses					
	Cost of Material Consumed					
	Purchase of Stock-in-Trade	-	2,391.07	0.01	2,391.07	120.71
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)					
	Employee Benefit Expenses	0.77	1.30	5.55	8.94	14.56
	Finance Cost			0.01	-	0.01
	Depreciation and Amortisation Expenses					
	Other expenses	8.95	3.08	2.60	17.15	8.95
	Total Expenses (IV)	9.72	2,395.45	8.16	2,417.15	144.23
V	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	(9.72)	9.71	1.95	2.02	1.89
VI	Exceptional Items					
VII	Profit/(Loss) before Tax (V-VI)	(9.72)	9.71	1.95	2.02	1.89
VIII	Tax Expense					
	(1) Current Tax	-	-	-	-	-
	(2) Deferred Tax	1.51	-	(0.05)	1.51	(0.05)
IX	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	(11.23)	9.71	2.01	0.51	1.94
X	Profit/(Loss) from Discontinued Operations	-	-	-	-	-
XI	Tax Expenses of Discontinued Operations					
XII	Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-	-
XIII	Profit/(Loss) for the Period (IX+XII)	(11.23)	9.71	2.01	0.51	1.94
XIV	Other Comprehensive Income					
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and other Comprehensive Income for the period)	(11.23)	9.71	2.01	0.51	1.94
XVI	Paid Up Equity Share Capital, Equity Shares Of Face Value Rs. 10 each	172.59	172.59	172.59	172.59	172.59
XVII	Earnings per Equity Share					
	(1) Basic	(0.65)	0.56	0.12	0.03	0.11
	(2) Diluted	(0.65)	0.56	0.12	0.03	0.11

Notes:

1. The above results were approved by Audit Committee and Board of Directors in their meeting held on 15th May 2025.
2. Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
3. Segment Results as per AS is not applicable as dealing in only one segment i.e. "Renewable Energy Sector Solar Cell Products".
4. No Investor Complaints were received during the quarter ended 31-March-2025 nor any pending as on 01-April-2025.
5. Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.

For S K Agarwal & Associates
 Chartered Accountants
 FRN: 014841C

CA Sushil Kumar Agarwal
 Partner
 M. No.: 403073
 Place: Rajkot
 Date: 15-May-2025
 UDIN: 25403073BMMJOFF5582



For and on behalf of the Board
 Sarada Proteins Ltd
 CIN: L15142RJ1991PLC006353

Thumar

Chirag Shantilal Thumar
 Managing Director
 DIN: 10640822

SARDA PROTEINS LTD

CIN: L15142RJ1991PLC006353

Regd. Off.: B-536-537, Matsya Industrial Area, Alwar, Rajasthan- 301030

Statement of Assets and Liabilities

As on 31st March, 2025

(Amount in Lakhs)

Particulars	Note No.	As at 31-Mar-2025	As at 31-Mar-2024
1 ASSETS			
Non- Current Assets			
a) Property, Plant and Equipment	6	-	0.01
b) Financial Assets			
(i) Investments	7	-	-
(ii) Loans & Advances	8	-	-
c) Deferred Tax Assets (Net)	9	12.04	13.55
d) Other Non- Current Assets		-	-
Total Non-Current Assets		12.04	13.56
Current Assets			
a) Inventories			
b) Financial Assets			
(i) Trade Receivables	10	-	-
(ii) Cash and Cash Equivalents	11	3.38	11.87
(iii) Loans & Advances	8	249.39	218.05
Total Current Assets		252.77	229.92
TOTAL ASSETS		264.81	243.48
2 EQUITY AND LIABILITIES			
Equity			
a) Share Capital	2	250.45	250.45
b) Other Equity (Reserve & Surplus)	3	-12.65	-13.16
Total Equity		237.80	237.29
Liabilities			
Non-current liabilities			
a) Financial Liabilities		2.50	-
b) Provisions	4	0.46	4.34
Total Non-Current Liabilities		2.96	4.34
Current Liabilities			
a) Financial Liabilities			
(i) Borrowings		-	-
(ii) Trade Payables		22.41	-
(iii) Other Financial Liabilities	5	1.63	1.84
(iii) Provisions	4	0.00	0.00
Total Current Liabilities		24.05	1.84
Total Liabilities		27.01	6.19
TOTAL EQUITY AND LIABILITIES		264.81	243.48
Significant Accounting Policies & Other Notes to Accounts:	1		
The accompanying notes are an integral part of the Financial Statements, as per our report of even date attached			
For S K Agarwal & Associates Chartered Accountants FRN: 014841C			
<i>Sushil Kumar Agarwal</i> Sushil Kumar Agarwal Partner M. No.: 403073 Date : 15.05.2025 Place : Rajkot UDIN: 25403073BMJOFF5582	<i>Yagnik Arvindbhal</i> Yagnik Arvindbhal Chief Financial Officer PAN: FXEPS6851M	<i>Namrata Karwa</i> Namrata Karwa Company Secretary M. No.: A58021	For and on behalf of Board Sarda Proteins Ltd CIN: L15142RJ1991PLC006353 <i>Thumar Ch. Khilan Hareeshbhai</i> Chirag Shantilal Thumar Managing Director DIN: 10640822 Khilan Hareeshbhai Savallya Director DIN: 08790209



SARDA PROTEINS LTD

CIN: L15142RJ1991PLC006353

Regd. Off.: B-536-537, Matsya Industrial Area, Alwar, Rajasthan- 301030

**Cash Flow Statement
For the year ended 31st March 2025**

(Amount in Lakhs)

Particulars	As at 31.03.2025	As at 31.03.2024
CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before Tax and extraordinary items	2.02	1.89
A. ADJUSTMENT FOR		
Depreciation	-	-
Interest Received	(0.06)	(16.53)
Profit on sale of Investment	-	0.13
Dividend	-	-
(Profit) /Loss on sale of Fixed Assets	0.01	-
Interest Paid	-	0.01
Operating profit/(Loss) before working capital charges	1.96	(14.51)
ADJUSTMENT FOR:		
Trade and other receivables	(31.34)	(9.67)
Inventories	-	-
Trade & other Payables	22.20	1.09
Other Non Current Liabilities	(3.88)	-
Other Non Current Assets	-	-
Cash generated from operations	(11.06)	(23.09)
Direct Taxes Paid	-	-
Net Cash from operating activities	(11.06)	(23.09)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Capital Expenditure	-	-
Sale of Fixed Assets	0.01	-
Profit on sale of Investment/Assets	(0.01)	(0.13)
Sale of Investment	-	0.13
Interest received	0.06	16.53
Dividend received	-	-
Net cash received from investing activities	0.06	16.53
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Long term borrowings	2.50	-
Proceeds from Short term borrowings	-	-
Interest paid	-	(0.01)
Net cash inflow/(outflow) from financing activities	2.50	(0.01)
Net cash increase/(Decrease) in cash and cash equivalents (A+B+C)	(8.49)	(6.56)
Cash & Cash Equivalants (Opening)	11.87	18.44
Cash & Cash Equivalants (Closing)	3.38	11.87


Significant Accounting Policies & Other Notes to Accounts: note 1
The accompanying notes are an integral part of the Financial Statements.
as per our report of even date attached


For S K Agarwal & Associates
Chartered Accountants
FRN: 014841C


For and on behalf of Board
Sarda Proteins Ltd
CIN: L15142RJ1991PLC006353


Sushil Kumar Agarwal


Yagnik Arvindbhai
Satasiya
Chief Financial Officer
PAN: FXEPS6831M


Namrata Karwa
Company Secretary
M. No.: A58021


Chirag Shantilal
Thumar
Managing Director
DIN: 10640822


Khilan Hareshbhai
Savaliya
Director
DIN: 08790209

Partner
M. No.: 403073
Date : 15.05.2025
Place : Rajkot
UDIN: 25403073RMJOFF5582



CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

Date: 15-05-2025

To,
Department of Corporate Service,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

SCRIP CODE: 519242

Subject: - Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended

Dear Sir / Madam,

I, Yagnik Arvindbhai Satasiya, Chief Financial Officer of Sarda Proteins Limited (CIN: L15142RJ1991PLC006353) having registered office situated at B-536-537, Matsya Industrial Area, Alwar, Alwar, Rajasthan, India, 301030 hereby declare that the Statutory Auditors of the Company M/s. S K Agarwal & Associates, (FRN No. 014841C), have issued an Audit Report with unmodified opinion on the Annual Audited Standalone Financial Results of the Company for the year ended March 31, 2025.

This declaration is given in Compliance to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

Kindly take aforesaid mentioned documents on your records.

Thanking you,

Yours faithfully,

For, Sarda Proteins Limited



Yagnik Arvindbhai Satasiya
Chief Financial Officer (CFO)
PAN: FXEPS6851M